| Name | Title | Contact Details |
|---|
St. Mary`s Healthcare offers a continuum of services designed to fulfill the total healthcare needs of the community, while being the lowest cost provider. In addition to our 143 bed hospital, a 160 bed nursing home and a 10 bed acute rehabilitation unit, St. Mary`s provides highly accessible healthcare through its seven offsite primary care centers and behavioral health service locations throughout two counties. We treat more than 290,000 outpatient visits a year. Founded by the Sisters of St. Joseph of Carondelet in 1903, and as a member of Ascension since 2002, St. Mary`s is dedicated to improving the health of the community with special attention to the poor and underserved. By addressing the spiritual, social, emotional and physical needs of our patients, we strive to provide an exceptional patient experience and a model community for our associates and medical staff.
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations.
NatLabs is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hospital Central Services is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.